|
Privacy Policy
Updated May 12, 2006
Allergan respects your privacy and recognizes your need for appropriate protection and management of personally identifiable information you share with us (the phrases "personally identifiable information" means any information by which you can be identified, such as your name, address, telephone number, etc.). The purpose of this privacy statement is to inform you what personally identifiable information we may collect from you when you visit our Site, and how we use such information, and the choices you have regarding our use of, and your ability to review and correct, the information. As we may revise our privacy policies from time to time, you should therefore periodically visit this page to review the then current Privacy Statement.
How We Collect Information
In general, you can visit many of our Web pages without telling us who you are or revealing any personally identifiable information. We may track the Internet domain address from which people visit us and analyze this data for trends and statistics, but individual users will remain anonymous, unless you voluntarily tell us who you are.
There may be times at which we ask you to provide certain information about yourself, such as your name, address, telephone number, e-mail address, etc. Whether or not to provide such information is completely your own choice; Allergan collects only the personal information that you provide to us. But if you choose not to provide the information we request, you may be unable to access certain services, offers, and content on our Site.
Cookies
To enable Allergan to provide customized and personalized services, Allergan may use cookies to store and sometimes track information about you. A cookie is a small amount of data that is sent to your browser from a Web server and stored on your computer. Cookies, by themselves, do not tell us any personally identifiable information about you. However, if you choose to furnish the Site with personally identifiable information (such as your e-mail address), that information could be linked to the data stored in the cookie. Allergan reserves the right to change our use of cookies and our practices regarding linkage to personally identifiable information without any prior notification.
How We Use Information
We use the information we automatically receive from your Web browser to see which pages you visit within our Site. We can then develop statistics that are helpful to understanding how this Site is used by our visitors. This statistical data is interpreted by Allergan in its continuing effort to present the Site content that visitors are seeking in a format they find most helpful.
When Allergan receives personally identifiable information, we may use it for reasonable business purposes, such as contacting you, via e-mail or regular mail, to provide you with information we believe may be of interest. If you e-mail us, you are voluntarily releasing information to us. Your e-mail address will be used by Allergan to respond to you.
Third-Party Use of Information
Allergan will not sell, share, or otherwise distribute your personally identifiable information to third parties except as provided herein. However, personally identifiable information may occasionally be transferred to third parties who act for or on behalf of Allergan, or in connection with the business of Allergan, for further processing in accordance with the purposes for which the data was originally collected. Your identity and the information you provide may be shared with your doctor. It will only be shared with your doctor if you have indicated to us that you would like to receive the quarterly e-mail newsletter and/or that you would like to receive future e-mail communications about Allergan products, programs, and services. Where disclosure of personally identifiable information to a third party is likely or necessary, further explanation may be provided, where appropriate, at such collection points as to the intended use of the data. We require that such third parties protect the information and, where appropriate, we will contractually require them to process data transferred only for the purposes expressly authorized by Allergan.
Because of the nature of the Internet, we may transmit the information to another country, but within Allergan, for purposes other than direct marketing, such as for storage, or because of where our servers are located. We may also use it to investigate security breaches or cooperate with authorities pursuant to a legal matter. We may also remove all the personally identifiable information and use the rest for historical, statistical, or scientific purposes. This Site contains links to other sites. Be aware that Allergan is not responsible for the privacy practices of non-Allergan sites. We encourage you to review the privacy statements of any Web sites that you visit through a link on this Site.
Children
In order to respect the privacy of children online, we do not knowingly collect, maintain, or process personal information submitted by children under the age of 13. If you have a child under the age of 13 who you believe may have provided information to us, please e-mail us at corpinfo@allergan.com and we shall expeditiously delete it.
Questions and Comments
If you have any questions or comments about Allergan's Privacy Policy or if you wish to review and correct your personally identifiable information held by Allergan, please contact us by clicking on the Contact link within the Site and by inserting the words "Privacy Policy" in the Subject line.
|
LATISSE™ (bimatoprost ophthalmic solution) 0.03% is indicated to treat hypotrichosis of the eyelashes by increasing their growth including length, thickness, and darkness.
Important Safety Information
Contraindications: LATISSE™ is contraindicated in patients with hypersensitivity to bimatoprost or any other ingredient in this product.
Warnings and Precautions: Bimatoprost ophthalmic solution (LUMIGAN®) lowers intraocular pressure (IOP) when instilled directly to the eye in patients with elevated IOP. In clinical trials, in patients with or without elevated IOP, LATISSE™ lowered IOP, however, the magnitude of the reduction was not cause for clinical concern. In ocular hypertension studies with LUMIGAN®, it has been shown that exposure of the eye to more than one dose of bimatoprost daily may decrease the intraocular pressure lowering effect. In patients using LUMIGAN® or other prostaglandin analogs for the treatment of elevated intraocular pressure, the concomitant use of LATISSE™ may interfere with the desired reduction in IOP. Patients using prostaglandin analogs including LUMIGAN® for IOP reduction should only use LATISSE™ after consulting with their physician and should be monitored for changes to their intraocular pressure.
Increased iris pigmentation has occurred when the same formulation of bimatoprost ophthalmic solution (LUMIGAN®) was instilled directly onto the eye. Although iridal pigmentation was not reported in clinical studies with LATISSE™, patients should be advised about the potential for increased brown iris pigmentation which is likely to be permanent.
Bimatoprost has been reported to cause pigment changes (darkening) to periorbital pigmented tissues and eyelashes. The pigmentation is expected to increase as long as bimatoprost is administered, but has been reported to be reversible upon discontinuation of bimatoprost in most patients.
Adverse Reactions: The most frequently reported adverse events were eye pruritus, conjunctival hyperemia, skin hyperpigmentation, ocular irritation, dry eye symptoms, and erythema of the eyelid. These events occurred in less than 4% of patients.
|